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Abstract To conWrm and reWne associations of human
leukocyte antigen (HLA) genotypes with variable antibody
(Ab) responses to hepatitis B vaccination, we have ana-
lyzed 255 HIV-1 seropositive (HIV+) youth and 80 HIV-1
seronegatives (HIV¡) enrolled into prospective studies. In
univariate analyses that focused on HLA-DRB1, -DQA1,
and -DQB1 alleles and haplotypes, the DRB1*03 allele
group and DRB1*0701 were negatively associated with the
responder phenotype (serum Ab concentration ¸ 10 mIU/mL)
(P = 0.026 and 0.043, respectively). Collectively,
DRB1*03 and DRB1*0701 were found in 42 (53.8%) out
of 78 non-responders (serum Ab <10 mIU/mL), 65 (40.6%)
out of 160 medium responders (serum Ab 10–1,000 mIU/
mL), and 27 (27.8%) out of 97 high responders (serum Ab
>1,000 mIU/mL) (P < 0.001 for trend). Meanwhile, DRB1*08
was positively associated with the responder phenotype
(P = 0.010), mostly due to DRB1*0804 (P = 0.008). These
immunogenetic relationships were all independent of non-
genetic factors, including HIV-1 infection status and immu-
nodeWciency. Alternative analyses conWned to HIV+ youth
or Hispanic youth led to similar Wndings. In contrast, analy-
ses of more than 80 non-coding, single nucleotide polymor-
phisms within and beyond the three HLA class II genes
revealed no clear associations. Overall, several HLA-DRB1
alleles were major predictors of diVerential Ab responses to
hepatitis B vaccination in youth, suggesting that T-helper
cell-dependent pathways mediated through HLA class II
antigen presentation are critical to eVective immune
response to recombinant vaccines.
Introduction
Hepatitis B virus (HBV) infection aVects 350–400 million
people globally (Custer et al. 2004; Dienstag 2008; Fatto-
vich et al. 2008; Lai and Yuen 2008; McGovern 2007).
Vaccines based on recombinant HBV surface antigen
(HBsAg) oVer a safe and eVective strategy for preventing
HBV infection, as anti-HBsAg antibody (Ab) concentra-
tions can exceed the minimum protective level of 10 mIU/mL
for up to 95% of healthy recipients. Nonetheless, lack of
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eYcacy can be a problem to vaccine recipients with
compromised or impaired immune system (Collier et al.
1988; Zuin et al. 1992), which has prompted the search for
further improvements through (a) increasing the amount of
antigen given in each injection (Cornejo-Juarez et al. 2006;
Cruciani et al. 2009; de Vries-Sluijs et al. 2008; Fonseca
et al.  2005; Pasricha et al. 2006), (b) adding an extra
(boosting) dose when the standard three-dose regimen fails
to induce protective Ab response (Cruciani et al. 2009; Rey
et al. 2000), and (c) using immunoregulatory cytokine or
unmethylated CpG oligonucleotide as an adjuvant in one of
the priming doses (Cooper et al. 2008; Sasaki et al. 2003).
Suboptimal Ab response to full-dose HBV vaccination
was common in adolescents and youth enrolled by the
Reaching for Excellence in Adolescent Care and Health
(REACH) study supported by the Adolescent Medicine Tri-
als Network for HIV/AIDS Interventions (ATN) (Wang
et al. 2004; Wilson et al. 2001). Key factors associated with
this unfavorable outcome included: (1) immunodeWciency
as a result of HIV-1 infection, (2) human leukocyte antigen
(HLA) class II genotype, especially DRB1*07, and (3) pro-
moter sequence variations in several cytokine genes (Wang
et al. 2004). To conWrm and reWne some of these Wndings,
new interventional studies nested within ATN have
enrolled youth for prospective evaluation of HBV vaccina-
tion. These studies have facilitated the systematic analyses
of HLA class II alleles and haplotypes in relation to diVer-
ential Ab responses to HBV vaccination. Genotypes deW-
ned by non-coding, single nucleotide polymorphisms
(SNPs) within and beyond the HLA class II region can also
be tested for their potential associations.
Methods
Study populations
Between February 2006 and June 2008, 255 HIV-1 sero-
positive (HIV+) youth (12–24 years of age) and 80 HIV-1
seronegatives (HIV¡) (12–17 years of age) were enrolled at
22 clinical sites (listed in Appendix) into prospective stud-
ies (http://www.clinicaltrials.gov/ct/show/NCT00142740)
(Table 1). The HIV¡ subjects were recruited from the US
and Puerto Rico, while the HIV+ youth came from US,
Puerto Rico, Brazil, and South Africa. The primary objec-
tive was to evaluate genetic inXuences on peak Ab
responses in patients with three full doses of hepatitis B
vaccination, based on analyses of eligible patients who
were free of hepatitis before completing full vaccination
regimens within the Wrst 24 weeks (6 months) after enroll-
ment. For HIV+ youth, their baseline CD4+ T cell counts
were also measured as potential covariates for immune
responses. This study was Wrst approved by the Institutional
Review Board (IRB) at University of Alabama at Birming-
ham (UAB), as protocol F051212004. Additional IRB
approval was obtained from each participating clinical site
before patients were asked to provide written informed con-
sent for participation. Import of patient specimens from
international sites in Brazil and South Africa to US was
approved by the Centers for Disease Control and Preven-
tion (permit no. 2006-12-053 and 2007-12-015).
QuantiWcation and categorization of serum 
Ab concentration
Using serum sample drawn at week 28, i.e., 4 weeks after
the  Wnal recommended dose of vaccine, Ab speciWc for
HBsAg was measured in a central laboratory (Quest Diag-
nostics Inc., Baltimore, MD), using two commercial assays
that diVer in their lower limits of detection (LLD) (3 and
5 mIU/mL). The vast majority (98.5%) of samples were
tested using the second assay, which provided an upper
limit of detection (ULD) at 1,000 mIU/mL. A small num-
ber of subjects had no remaining serum to allow re-measure
and so these subjects only had Ab results reported using the
Wrst test (ULD at 150 mIU/mL). Patients with peak serum
Ab concentration less than 10 mIU/mL (the minimum
protection level) were classiWed as non-responders (NR).
Those with Ab concentrations ranging from 10 to
1,000 mIU/mL were designated as medium responders
(MR), while high responders (HR) were the remainder of
patients with Ab concentrations over 1,000 mIU/mL.
Table 1 Characteristics of 335 youth with deWned peak antibody (Ab)
response to full-dose hepatitis B vaccination
a By comparing the two patient groups using either t test (for age) or
logistic regression (for other variables)
b Treated as one group in subsequent analyses (e.g., Table S2)
c Non-responders have serum Ab concentrations <10 mIU/mL at week
28 (4 weeks after last dose of vaccination); medium responders at
10–1,000 mIU/mL; high responders >1,000 mIU/mL
HIV-1 
seropositive
(N =2 5 5 )
HIV-1 
seronegative 
(N = 80)
P valuea
Baseline age (mean § SD) 20.9 § 0.2 15.8 § 0.2 <0.0001
Sex ratio (F/M) 1.60 (157/98) 0.57 (29/51) <0.0001
Race/ethnicity combined 0.230
Black, non-Hispanic 76 (29.8) 17 (21.3%)
White, non-Hispanicb 7 (2.8) 2 (2.5)
Hispanic (Black or White) 169 (66.3) 60 (75.0)
Othersb 3 (1.2) 1 (1.3)
Ab responsec <0.0001
Non-responder (NR) 74 (29.0%) 4 (5.0%)
Medium responder (MR) 121 (47.5%) 39 (48.8%)
High responders (HR) 60 (23.5%) 37 (46.3%)Hum Genet (2009) 126:685–696 687
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PCR-based genotyping of three HLA class II genes 
(HLA-DRB1, -DQA1, and -DQB1) in the human major 
histocompatibility complex (MHC)
Using DNA extracted from whole blood or buVy coat
(PureGen kits from Gentra/Qiagen, Valencia, CA, USA),
HLA-DQA1 and -DQB1 alleles were resolved with auto-
mated hybridization of sequence-speciWc oligonucleotide
(SSO) probes to gene-speciWc PCR amplicons (Innogenet-
ics Inc., Alphartetta, GA). Tests were facilitated by the
Auto LiPA 30 system, under conditions recommended by
the manufacturer (Innogenetics). A total of 35 and 37 SSO
probes were used for HLA-DQA1 and -DQB1 typing,
respectively. Homozygosity was conWrmed and ambiguities
with SSO results were resolved by sequencing-based typing
(SBT), using commercial kits from Abbott Molecular Inc.
(Des Plaines, IL). HLA-DRB1 genotyping began with SBT
(Abbott Molecular Inc.), with ambiguities resolved by SSO
assays (57 probes) (Innogenetics). The same or similar
genotyping techniques had been applied extensively in ear-
lier studies involving samples from African, European, and
North American populations (Shao et al. 2004; Tang et al.
2004, 2008). The Wnal allele assignments for the three HLA
class II genes considered two major functional properties.
First, allele groups deWned by the Wrst two-digit designa-
tions (e.g., DRB1*01) often correspond to serological spec-
iWcities (as alloantigens) (Schreuder et al. 2005) or shared
motifs and lineages (Agrawal et al. 2007; Bergstrom et al.
1999; Dorak et al. 2006; Hohjoh et al. 2003). Second, alle-
les with four-digit designations (e.g., DRB1*0101, *0102,
and *0103) deWne functional units that diVer in amino acid
sequences and the protein structure. Higher (six-digit) reso-
lution like DRB1*010201 was also achievable for various
alleles in the study population, with the 5th and 6th digits
capturing additional, synonymous DNA polymorphisms.
However, only DRB1*1101 had multiple common alleles
with diVerent six-digit designations (i.e., *110101 and
*110102) in the study population. Further intronic sequence
polymorphisms reXected by the 7th and 8th digits were not
considered because intronic sequences were not part of our
HLA genotyping strategies and because only a small num-
ber of alleles have such known designations (Robinson
et al. 2006).
Computational assignment of HLA class II haplotypes
Following resolution of individual HLA alleles at each
locus, linkage disequilibrium (LD) between speciWc HLA
allele groups (two-digit designations) and alleles (four-digit
designations) at neighboring loci were determined by rela-
tive diVerence (D) between the observed and expected fre-
quencies of co-existence (presence) on the same
chromosome or by correlation coeYcients (r). Two-locus
haplotype assignments were based on the expectation-max-
imization (EM) algorithm in SAS Genetics (SAS Institute,
Cary, NC), which was further applied to the evaluation of
extended, three-locus haplotypes. All haplotypes assigned
computationally were unambiguous, with statistical proba-
bility exceeding 99%.
Primary association analyses of HLA class II variants
Using SAS program package, version 9.2 (including SAS
Genetics) (SAS Institute), the distribution of HLA class II
alleles and haplotypes was Wrst assessed for Hardy–Wein-
berg equilibrium (HWE) among patient groups deWned by
race, ethnicity, HIV-1 infection status, and Ab responses
(NR, MR, and HR). Population (marker) frequencies of
HLA allele groups, alleles, and their haplotypes were then
compared across the three groups of patients deWned by
Ab responses. Individual variants with nominal P < 0.050
in univariate tests for trend (logit procedure) were further
evaluated in multivariable logistic regression models.
DiVerent model selection procedures (backward, forward,
stepwise) were applied until a reduced model could suY-
ciently capture all independent predictors of the responder
phenotype. The summary statistical measures included
eVective sample sizes as well as strengths of associations,
as indicated by beta estimates (mean § standard error),
proportional odds ratio (pOR) across three Ab response
groups (HR, MR, and NR), OR for being responders
(HR + MR vs. NR), 95% conWdence interval (CI) for all
pOR and OR estimates, along with P values (either nomi-
nal or adjusted).
Genotyping of SNPs within and beyond the HLA class II 
region
Single nucleotide polymorphism selection focused on three
major genomic blocks within and between HLA class I and
class II genes (Table S1). The Wrst (HLA class I region) has
three genes (ZNRD1, HLA-C, and HCP5) recently impli-
cated as important to HIV-1 pathogenesis in several
genome-wide association studies (Dalmasso et al. 2008;
Fellay et al. 2007; Limou et al. 2009) and additional fol-
low-up studies (Catano et al. 2008; Shrestha et al. 2009;
van Manen et al. 2009). The second (central HLA region)
has a cluster of genes (TNF, LTA, and LTB) encoding tumor
necrosis factor alpha (TNF-), lymphotoxin alpha (LT- or
TNF-), and LT- that regulate inXammatory responses.
The third (HLA class II region) has multiple non-coding
SNPs that can eVectively tag HLA class II alleles associ-
ated with autoimmune and related diseases (de Bakker et al.
2006). Gene-speciWc SNPs in HLA class I and central
regions were selected in Wve steps. First, SNPs assembled
through SNPper (http://snpper.chip.org/bio/snpper-explain)688 Hum Genet (2009) 126:685–696
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were Wltered to allow an initial focus on “functional SNPs”
with a potential phenotypic eVect, including those located
in exons, transcription factor binding sites, and intron/exon
boundaries. Second, SNPs with minor allele frequencies
(MAF) <0.02 in any of the three major populations
(Africans, Asians, and Europeans) targeted by the Interna-
tional HapMap Project (http://www.hapmap.org/cgi-perl/
gbrowse/hapmap26_B36/) were excluded for lack of statis-
tical power. Third, the Tagger program (http://www.broad.
mit.edu/mpg/tagger/) was applied to select additional tag-
ging SNPs (tagSNPs) that would capture multiple SNPs
using a stringent tagging algorithm (r2 ¸ 0.8), with the r2
values derived from the HapMap project or the Perlegen
Genotype Browser (http://genome.perlegen.com/browser/
index.html). Fourth, SNPs commonly analyzed in earlier
population studies (de Bakker et al. 2006; Fellay et al.
2007) were added to serve as benchmarks that could facili-
tate inter-cohort comparisons. Fifth, SNPs chosen after the
Wrst four steps were evaluated for their respective suitabil-
ity for bead array-based genotyping (Goldengate SNP typ-
ing assay) at Illumina (San Diego, CA). SNPs predicted to
have low (<50%) success rates were replaced by new ones
of equal tagging capabilities. The last (Wfth) step was
repeated twice to yield a total of 88 (3 coding and 85 non-
coding) SNPs (Table S1) for high-throughput genotyping,
with quality control facilitated by previously genotyped ref-
erence DNA and by random duplicates of DNA samples
derived from the study population.
Statistical approach to analyzing SNP genotypes
For each of the 88 MHC SNPs analyzed here, homozygous
and heterozygous genotypes were tested in 3 £ 3 and
3 £ 2 contingency tables, i.e., patients with (2 or 1 copy)
and without (0 copy) the minor allele at each locus were
stratiWed by the three levels of Ab response (NR, MR, and
HR). A nominal P value < 0.050 in Chi-square test was
considered indicative of possible associations and all
neighboring SNPs were evaluated jointly for potential
involvement of local haplotypes. Evaluation of the relative
and independent contribution of SNP alleles and haplo-
types required statistical adjustments for HLA and non-
genetic factors revealed by primary association analyses.
Given the multiple testing of 88 target SNPs, about four
random (false positive) discoveries were anticipated when
type I statistical error was accepted at the 0.050 level,
while a truly probable association would require a P value
·5.7 £ 10¡4 to withstand correction for multiple compari-
sons. As a compromise between least and most stringent
evaluations, formal multivariable statistical models were
considered useful only for SNP variants with P < 0.001 in
the initial univariate tests.
Results
Patient characteristics and assessment of non-genetic 
factors in Ab responses
Among the 255 HIV-1 seropositive (HIV+) and 80 seroneg-
ative (HIV¡) youth enrolled into this study, HIV¡ individu-
als had a mean age of 15.8 years and they were mostly male
(63.8%) and Hispanic (75.0%). HIV+ individuals were
slightly older (average age = 20.9 years, P < 0.0001 when
compared with HIV¡ subjects) and they were mostly
female (61.6%) and Hispanic (66.3%).
As seen in analyses of another youth population (Wang
et al.  2004; Wilson et al. 2001), Ab response clearly
diVered between HIV+ and HIV¡ recipients (Table 1).
More speciWcally, 5.0% of HIV¡ subjects were classiWed as
NR (Ab concentration <10 mIU/mL), 48.8% as MR (10–
1,000 mIU/mL), and 46.3% as HR (>1,000 mIU/mL),
while HIV+ subjects had 29.0% NR, 47.5% MR, and 23.5%
HR (overall P < 0.0001 by logistic regression). In univari-
ate analysis, the negative impact of HIV-1 infection was
clearly reXected by the mean parameter () estimate and
standard error (SE) (¡0.61 § 0.13, P < 0.0001), along with
the estimates of proportional odds ratio (pOR = 0.29) and
95% conWdence interval (CI) (0.18–0.48) in test for trend
across the three patient groups deWned by high to low Ab
responses (i.e., ordered as HR, MR, and NR) (Table 2). To
minimize potential confounding by non-genetic factors, all
subsequent association analyses considered age, sex, eth-
nicity, and HIV-1 infection status as cofactors (whenever
possible).
Distribution and LD of HLA class II variants
Before any stratiWcation, common allele groups found in at
least ten individuals ranged from Wve at HLA-DQA1 and
-DQB1 loci to 12 at the HLA-DRB1 locus. These allele
groups contributed to 18 common DRB1–DQB1 haplo-
types. Distribution of homozygous and heterozygous geno-
types at each locus did not deviate from HWE, even for
subsets of HLA typing results restricted to either racial
groups or HIV-1 infection status (data not shown). Simi-
larly, distribution of four-digit alleles also conformed to
HWE, and the common alleles detected at each locus
ranged from 12 at the HLA-DQA1 locus to 25 at the HLA-
DRB1 locus. Twenty DRB1–DQB1 haplotypes were also
common in tabulations based on the four-digit allelic desig-
nations.
LD was quite strong for many four-digit alleles resolved
at the three HLA class II loci, leading to the unambiguous
(probability >99%) assignment of three-locus haplotypes in
all 335 individuals. However, within the three main racialHum Genet (2009) 126:685–696 689
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groups (Table 1), pairs of common alleles with strong
enough LD (r2 ¸ 0.80) to be mutually tagging were limited
to (a) DRB1*0301 versus DQB1*0201 (r = 0.82–0.95),
(b) DRB1*0301 versus DQA1*0501 (r = 0.92–1.00), (c)
DRB1*0701 versus DQA1*0201 (r = 0.86–0.98), (d) DR
B1*1101 versus DQA1*0105 (r = 0.72–0.94), (e) DRB1
*1301 versus DQB1*0603 (r = 0.81–0.92), (f) DRB1*
1401 versus DQA1*0104 (r = 0.92–1.00), (g) DRB1*
1401 versus DQB1*0503 (r = 0.92–1.00), (h) DRB1*1402
versus DQB1*0503 (r = 0.89–0.92), (i) DRB1*1502 versus
DQB1*0601 (r = 0.71–1.00), (j) DQA1*0501 versus DQB1*
0201 (r = 0.83–0.96), and (k) DRB1*0301–DQB1*0201
haplotype versus DQA1*0501 (r = 0.92–1.00). These
allele combinations and their two-digit allele groups
were treated as joint entities in order to minimize the
number of tests for genetic associations with variable Ab
responses.
As HIV-1 infection status alone was a strong predictor of
suboptimal Ab response, HLA class II alleles and haplo-
types that were diVerentially (P < 0.050) distributed among
HIV+ and HIV¡ subjects were also sorted (Table S2). Alle-
les enriched in HIV¡ subjects were DRB1*0407,
DRB1*0802, and DQA1*0301. Alleles enriched in HIV+
subjects were DRB1*0804, DQA1*0103, DQB1*0503, and
DQB1*0603 (Table S2).
Individual HLA class II variants in relation to diVerential 
Ab responses in the entire study population
Primary association analyses tested the key hypothesis that
HLA class II alleles and/or haplotypes, especially those
observed in another youth population (Wang et al. 2004),
correlate with variable Ab response to hepatitis B vaccina-
tion, irrespective of other characteristics of the study popu-
lation. After accounting for sample size (statistical power)
and patterns of LD (genetic confounding), four allele
groups stood out to be the most likely predictors of diVeren-
tial Ab responses (Table 2). First, DRB1*03 (mostly *0301
and *0302) and DRB1*07 (exclusively *0701) were nega-
tively associated with the responder phenotype, with simi-
lar eVective sample size (n = 71 for both),  estimates
(¡0.56 for both) and P values (·0.043), as well as similar
pOR (· 0.60). Second, DRB1*08 seen in 51 patients had a
positive association ( = 0.75, P = 0.010; pOR = 2.11, 95%
CI = 1.20–3.72), mostly due to DRB1*0804 (n = 21,
 =1 . 1 7§ 0.44,  P = 0.008; pOR = 3.22, 95% CI = 1.35–
7.63). In contrast, DRB1*0802 (Table S2) as another com-
mon allele in the DRB1*08 group did not show a clear
trend for positive or negative association (n = 16,
 =0 . 1 8§ 0.48,  P > 0.70), neither did the less frequent
allele DRB1*0801 (n =9 ,   =0 . 7 4§ 0.64,  P =0 . 2 4 9 ) .
Third, DQB1*02, which was found in 116 patients and in
LD with DRB1*03 (r = 0.32–0.43,  P · 0.0001) and
T
a
b
l
e
2
U
n
i
v
a
r
i
a
t
e
 
a
n
d
 
m
u
l
t
i
v
a
r
i
a
b
l
e
 
m
o
d
e
l
s
 
t
o
 
c
o
m
p
a
r
e
 
r
e
l
a
t
i
v
e
 
i
m
p
a
c
t
 
o
f
 
H
I
V
-
1
 
i
n
f
e
c
t
i
o
n
 
a
n
d
 
H
L
A
 
a
l
l
e
l
i
c
 
v
a
r
i
a
n
t
s
 
o
n
 
a
n
t
i
b
o
d
y
 
r
e
s
p
o
n
s
e
s
 
a
m
o
n
g
 
3
3
5
 
y
o
u
t
h
a
I
n
 
a
n
a
l
y
s
e
s
 
o
f
 
t
h
r
e
e
 
c
a
t
e
g
o
r
i
e
s
 
o
f
 
a
n
t
i
b
o
d
y
 
r
e
s
p
o
n
s
e
s
 
(
T
a
b
l
e
1
)
,
 
s
u
m
m
a
r
y
 
s
t
a
t
i
s
t
i
c
a
l
 
m
e
a
s
u
r
e
s
 
i
n
c
l
u
d
e
 
b
e
t
a
 
e
s
t
i
m
a
t
e
 
(
m
e
a
n
§
s
t
a
n
d
a
r
d
 
e
r
r
o
r
)
,
 
p
r
o
p
o
r
t
i
o
n
a
l
 
o
d
d
s
 
r
a
t
i
o
 
(
p
O
R
)
,
 
a
n
d
 
9
5
%
 
c
o
n
W
d
e
n
c
e
i
n
t
e
r
v
a
l
 
(
C
I
)
,
 
a
s
 
d
e
s
c
r
i
b
e
d
 
i
n
 
t
h
e
 
t
e
x
t
b
A
g
e
,
 
e
t
h
n
i
c
i
t
y
,
 
a
n
d
 
s
e
x
 
a
r
e
 
t
r
e
a
t
e
d
 
a
s
 
a
d
d
i
t
i
o
n
a
l
 
c
o
v
a
r
i
a
t
e
s
 
i
n
 
t
h
e
s
e
 
m
o
d
e
l
s
c
S
t
r
o
n
g
 
l
i
n
k
a
g
e
 
d
i
s
e
q
u
i
l
i
b
r
i
u
m
 
b
e
t
w
e
e
n
 
t
h
e
s
e
 
D
R
B
1
 
v
a
r
i
a
n
t
s
 
a
n
d
 
D
Q
B
1
*
0
2
 
(
*
0
2
0
1
 
a
n
d
 
*
0
2
0
2
)
 
p
r
e
c
l
u
d
e
s
 
t
h
e
i
r
 
p
r
e
s
e
n
c
e
 
i
n
 
a
 
s
i
n
g
l
e
 
m
o
d
e
l
 
(
N
A
 
n
o
t
 
a
p
p
l
i
c
a
b
l
e
)
F
a
c
t
o
r
s
 
(
c
o
v
a
r
i
a
t
e
s
)
n
U
n
i
v
a
r
i
a
t
e
 
a
n
a
l
y
s
e
s
a
M
u
l
t
i
v
a
r
i
a
b
l
e
 
m
o
d
e
l
 
1
b
M
u
l
t
i
v
a
r
i
a
b
l
e
 
m
o
d
e
l
 
2
b

§
S
E
P
p
O
R
9
5
%
 
C
I

§
S
E
P
p
O
R
9
5
%
 
C
I

§
S
E
P
p
O
R
9
5
%
 
C
I
H
I
V
-
1
 
i
n
f
e
c
t
i
o
n
2
5
5
¡
0
.
6
1
§
0
.
1
3
<
0
.
0
0
0
1
0
.
2
9
0
.
1
8
–
0
.
4
8
¡
0
.
6
0
§
0
.
1
6
0
.
0
0
2
0
.
3
0
0
.
1
6
–
0
.
5
6
¡
0
.
5
9
§
0
.
1
6
<
0
.
0
0
1
0
.
3
1
0
.
1
6
–
0
.
5
7
D
R
B
1
*
0
3
c
7
1
¡
0
.
5
6
§
0
.
2
5
0
.
0
2
6
0
.
5
7
0
.
3
5
–
0
.
9
3
¡
0
.
5
5
§
0
.
2
7
0
.
0
4
0
0
.
5
8
0
.
3
4
–
0
.
9
8
N
A
c
N
A
c
D
R
B
1
*
0
7
0
1
c
7
1
¡
0
.
5
6
§
0
.
2
5
0
.
0
4
3
0
.
6
0
0
.
3
7
–
0
.
9
8
¡
0
.
5
8
§
0
.
2
6
0
.
0
2
5
0
.
5
6
0
.
3
4
–
0
.
9
3
N
A
c
N
A
c
D
R
B
1
*
0
8
0
4
2
1
1
.
1
7
§
0
.
4
4
0
.
0
0
8
3
.
2
2
1
.
3
5
–
7
.
6
3
1
.
3
1
§
0
.
4
7
0
.
0
0
5
3
.
6
9
1
.
4
8
–
9
.
2
1
1
.
3
7
§
0
.
4
6
0
.
0
0
3
3
.
9
2
1
.
5
9
–
9
.
6
9
D
Q
B
1
*
0
2
1
1
6
¡
0
.
5
0
§
0
.
2
2
0
.
0
2
0
0
.
6
0
0
.
4
0
–
0
.
9
3
N
A
c
¡
0
.
3
7
§
0
.
2
2
0
.
1
0
0
0
.
6
9
0
.
4
5
–
1
.
0
8690 Hum Genet (2009) 126:685–696
123
DRB1*07 (r = 0.55–0.72, P · 8.0 £ 10¡10), paralleled the
associations of the two DRB1 allele, with similar parameter
estimates ( = ¡0.50 § 0.22, P = 0.020; pOR = 0.60, 95%
CI = 0.40–0.93).
In multivariable models, the impact of three HLA-DRB1
variants on Ab responses was clearly independent of one
another and these associations were insensitive to statistical
adjustments for the eVects of HIV-1 infection and other
potential confounders (adjusted P = 0.005–0.040) (Table 2).
Alternating DRB1*03 and DRB1*0701 with DQB1*02 did
not change the parameter estimates for non-genetic factors
and DRB1*0804, but it was evident that DQB1*02 itself
was not a statistically signiWcant factor (adjusted P = 0.100)
(Table 2). Collectively, DRB1*03 and DRB1*0701
were found in 42 (53.8%) out of 78 NR, 65 (40.6%) out
of 160 MR, and 27 (27.8%) out of 97 HR (P < 0.001 for
trend).
Evaluation of HLA haplotypes in the entire study 
population
Associations attributed to individual DRB1 alleles or allele
groups were partially reXected by several DRB1-DQB1
haplotypes (Table S2). For example, the negative impact of
DRB1*03 and DRB1*07 on Ab response was mostly due to
the DRB1*03–DQB1*04 (DRB1*0302–DQB1*0402)
haplotype ( = ¡0.75 § 0.41,  P = 0.067) and the DRB1
*07–DQB1*02 (DRB1*0701–DQB1*0202) haplotype
( = ¡0.48 § 0.26,  P = 0.066), respectively. The positive
association of DRB1*08 was mainly because of DRB1*08–
DQB1*03 (n =2 2 ,    =1 . 1 7§ 0.43,  P = 0.007) or
DRB1*0804–DQB1*0301 (n =1 8 ,    =1 . 2 6§ 0.48,
P = 0.009), but not DQB1*0301 itself (n =1 0 8 ,
 =0 . 2 3§ 0.22, P = 0.290). The parameter estimates for
the major haplotypes involving DRB1*08 were highly
comparable with those for DRB1*0804 alone (Table 2).
Further analyses of extended (three-locus) haplotypes did
not yield any deWnitive relationships.
Two alternative models to allow inter-study comparisons
To facilitate direct comparison with earlier Wndings based
on vaccine recipients without apparent immunodeWciency,
27 HIV+ subjects with severe immunodeWciency (<200
CD4+ T cells/L) were excluded from the testing of an
alternative model (Table 3). DRB1*03, DRB1*0701, and
DRB1*0804 remained as cofactors associated with diVer-
ential Ab responses (P = 0.002–0.006), even after statistical
adjustment for residual eVects of HIV-1 infection and other
non-genetic factors. A second alternative model used the
strategy tested in another cohort of youth (Wang et al.
2004), when responders were not further diVerentiated into
HR and MR groups. Again, DRB1*03 and *0701 were
independently associated with diVerential Ab response
status (Table 3), with similar parameter estimates
( = ¡0.88 § 0.35 and ¡1.03 § 0.36, P = 0.013 and 0.005,
respectively). The eVect of DRB1*0804 could not be reli-
ably established, as the allele was only present in the aggre-
gated responder group (HR + MR).
Analyses restricted to 255 HIV+ subjects
Stepwise analyses were further applied to the 255 HIV+
individuals alone (Table 4). By univariate analyses, severe
immunodeWciency (<200 CD4+ T cells/L) and moderate
immunodeWciency (200–450 CD4+ T cells/L) had a
strong negative impact on Ab responses (P <0 . 0 0 1 ) .
DRB1*0701 became a minor factor (n =5 6 ,  P = 0.159)
when compared with DRB1*03 (n =5 8 ,  P = 0.039) and
DRB1*0804 (n = 18,  P = 0.003). Two additional DRB1
variants, DRB1*04 (n = 44,  P = 0.054) and DRB1*15
(n =5 5 ,  P = 0.092), were recognized as marginally unfa-
vorable and favorable, respectively, with the latter found
exclusively on the DRB1*15–DQB1*06 haplotype. Only
DRB1*03, DRB1*0701, and DRB1*0804 could be retained
as independent factors (adjusted P = 0.005–0.029) in the
reduced multivariable model, after statistical adjustments
Table 3 Additional multivariable models to facilitate direct comparison with some of the earlier Wndings
a These analyses are restricted to 308 patients, when 27 HIV+ patients with severe immunodeWciency (<200 CD4+ T cells/L) are excluded. First
model tests three ordered groups of patients (HR, MR, and NR), while the second tests two patient groups, i.e. (HR + MR) versus NR. In both
models, age, ethnicity, and sex are treated as additional covariates for statistical adjustments
b DRB1*0804 is not suited for model 2 as it is only found in responders (HR + MR); NA not applicable
Factors 
(covariates)
n Alternative multivariable model 1a Alternative multivariable model 2a
 § SE P pOR 95% CI  § SE P OR 95% CI
HIV-1 infection 228 ¡0.44 § 0.17 0.010 0.42 0.22–0.81 ¡0.73 § 0.31 0.021 0.23 0.07–0.80
HLA variants
DRB1*03 67 ¡0.78 § 0.28 0.006 0.46 0.26–0.80 ¡0.88 § 0.35 0.013 0.42 0.21–0.83
DRB1*0701 67 ¡0.84 § 0.28 0.002 0.43 0.25–0.74 ¡1.03 § 0.36 0.005 0.36 0.18–0.73
DRB1*0804b 20 1.37 § 0.49 0.006 3.93 1.50–10.31 NA NAHum Genet (2009) 126:685–696 691
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for the clear, negative impact of severe and moderate
immunodeWciency (P < 0.001). Thus, replacing HIV-1
infection status (Table 2) with CD4+ T cell count as a key
non-genetic factor did not alter the independent associa-
tions of three HLA-DRB1 variants with Ab responses.
Analyses conWned to 229 Hispanic subjects
In further analyses conWned to 229 Hispanics (Table 5), a
reduced multivariable model continued to conWrm the neg-
ative impact of HIV-1 infection on Ab responses
(P < 0.0001). DRB1*0804 (n = 11) and DRB1*15 (n = 47)
were the only HLA class II variants independently associ-
ated with Ab responses (adjusted P = 0.045 and 0.019,
respectively). Analyses of other alleles (including
DRB1*03 and DRB1*0701) and their haplotypes were
inconclusive because of reduced statistical power.
Secondary analyses of SNPs
Secondary analyses tested the hypothesis that non-coding
SNPs in and around HLA class II genes might also be con-
tributory, because of their potential inXuence on gene
expression and/or mRNA splicing, as implied by genome-
wide association studies (Dalmasso et al. 2008; Fellay et al.
2007; HaXer et al. 2007; Kuniholm 2007; Limou et al.
2009). A panel of 88 SNPs within three blocks of human
MHC was successfully genotyped in 280 patients with at
least 2 g of high-quality DNA at the completion of HLA
genotyping. One SNP (rs2523685) mapped to MHC class I
region had a nominal P value at 0.021 in test of SNP geno-
types among the three Ab response groups (Fig. 1). This
weak association was driven by the heterozygous genotype
(rs2523685CG), which was present in 31 (37.8%) out of 82
HR, 70 (49.3%) out of 142 MR, and 33 (58.9%) out of 56
NR patients. Homozygosity for the minor allele (genotype
GG) had no trend (24.4% HR, 14.1% MR, and 21.4% NR).
The putative association of rs2523685 genotypes with
diVerential Ab responses could be dismissed for three rea-
sons. First, the rs2523685 SNP is mapped to the 5 Xanking
region (distant from the promoter sequences) of HCP5
(Table S2), without any predicted or known functional rele-
vance for either allele. Second, likelihood of chance associ-
ation was high—about two random associations were
Table 4 Analyses conWned to 255 HIV-1 seropositive (HIV+) youth
a Univariate analyses correspond to tests for trend across three patient groups (HR, MR, and NR), while multivariable model highlights all inde-
pendent factors (with further statistical adjustments for potential confounding by age, ethnicity, and sex). NA not applicable (adjusted P > 0.050)
b As measured at baseline (time of enrollment). Patients with >450 CD4+ T cell counts/L serve as the reference group
c Other variants are dismissed by univariate and multivariable analyses
d In these 55 patients, DRB1*15–DQB1*06 is the only haplotype involving DRB1*15
Individual factors 
(covariates)
n Parameters from univariate analysesa Reduced multivariable modela
 § SE P pOR 95% CI  § SE P pOR 95% CI
<200 CD4+ T cells/Lb 27 ¡2.69 § 0.48 <0.0001 0.07 0.03–0.18 ¡2.95 § 0.50 <0.0001 0.06 0.02–0.14
200–450 CD4+ T cells/Lb 96 ¡1.01 § 0.26 <0.001 0.36 0.22–0.61 ¡1.03 § 0.27 <0.001 0.36 0.21–0.61
Individual HLA variantsc
DRB1*03 58 ¡0.58 § 0.28 0.039 0.56 0.32–0.97 ¡0.67 § 0.31 0.029 0.51 0.28–0.93
DRB1*04 44 ¡0.61 § 0.31 0.054 0.55 0.35–1.01 NA NA
DRB1*0701 56 ¡0.40 § 0.28 0.159 0.67 0.38–1.17 ¡0.68 § 0.31 0.026 0.50 0.28–0.92
DRB1*0804 18 1.40 § 0.48 0.003 4.06 1.59–10.34 1.44 § 0.51 0.005 4.23 1.55–11.58
DRB1*15d 55 0.49 § 0.29 0.092 1.62 0.93–2.85 NA NA
Table 5 Multivariable analyses conWned to 229 Hispanic youth
a Following similar strategies shown in Table 4, except that (i) status of HIV-1 infection replaces CD4+ T cell count as the primary non-genetic
factor; (ii) only age and sex are treated as additional covariates
b Other HLA variants, including DRB1*03 and DRB1*0701, are dismissed (adjusted P > 0.050)
Individual factors (covariates) n Reduced multivariable modela
 § SE P pOR 95% CI
HIV-1 infection 169 ¡0.83 § 0.21 <0.0001 0.19 0.08–0.43
Individual HLA variantsb
DRB1*0804 11 1.26 § 0.63 0.045 3.53 1.03–12.06
DRB1*15 47 0.77 § 0.33 0.019 2.16 1.13–4.10692 Hum Genet (2009) 126:685–696
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expected from the tests of 88 SNPs when P value was
accepted at 0.021. Alternatively, 1.3 random associations
were expected from the tests of 62 MHC class I SNPs
alone. Third, the SNP is remote from the HLA class II
genes that produced the strongest signals in all analyses.
Discussion
Our analyses of three HLA class II genes in 335 youth con-
Wrmed the negative impact of DRB1*03 and DRB1*0701
on peak Ab responses to HBV vaccination, as reported in
prior studies of infant, adolescent, and adult populations
(Belloni et al. 1993; Caillat-Zucman et al. 1998; Craven
et al. 1986; del Canho et al. 1993; Hatae et al. 1992; Hohler
et al.  1998,  2002b; Kramer et al. 1988; Martinetti et al.
1995; McDermott et al. 1997; Peces et al. 1997; Qian et al.
2002; Wang et al. 2004; Watanabe et al. 1988; Weissman
et al. 1988). Although our study relied heavily on Hispanics
and HIV+ youth, the main Wndings most closely resembled
those reported earlier for adults of European ancestry
(Hohler et al. 1998). Studies on patients with natural HBV
infection lend further support for these immunogenetic
Wndings, as HLA haplotypes having either DRB1*03 or
DRB1*07 were enriched in patients who were unable to
clear HBV after infection (Thio et al. 2003). In addition, as
both DRB1*03 and DRB1*0701 are in strong LD with
DQB1*02 (DQ2 by serology), their relationships to Ab
responses were partially reXected by DQB1*02 (Belloni
et al. 1993; Hohler et al. 1998; Martinetti et al. 1995, 2000;
McDermott et al. 1997; Peces et al. 1997; Stachowski et al.
1995).
In population-based analyses of diverse HLA alleles,
statistical power (sample size and allele frequency), false
discoveries, and population heterogeneity are some of the
major concerns. The HLA-DRB1 variants negatively associ-
ated with Ab responses were relatively common in our
study population, but statistical power alone could not
account for these key Wndings because statistical power
actually favored the analyses of HLA-DQA1 and -DQB1
variants, which are much less diverse than HLA-DRB1 alle-
les. False discovery was also unlikely because various stud-
ies have led to similar conclusions. Indeed, even the minor
Wnding on DRB1*15 (DR2 by serology), which appeared to
be a favorable factor in HIV+ youth (Table 4), was also
consistent with evidence from studies of infants and adults
(Caillat-Zucman et al. 1993; Hohler et al. 1998). Population
heterogeneity, on the other hand, could obscure causal rela-
tionships when analyses can only survey tagging variants
instead of the functional units. However, heterogeneity in
ethnic backgrounds could not compromise our major Wnd-
ings at least for three reasons. First, individual HLA alleles
encode structurally and functionally distinct protein prod-
ucts that facilitate immune surveillance regardless of racial
or ethnic background (Jones et al. 2006). Second, parame-
ter estimates for DRB1*03 and DRB1*0701 were mostly
insensitive to statistical adjustments for non-genetic factors,
including race/ethnicity (Table 2). Third, our analyses dis-
missed the potential confounding by other genetic variants,
especially those (e.g., DQB1*0201 and DQB1*0202) that
are known to be in strong LD with DRB1*03 and
DRB1*0701 (Table 2).
HLA class II alleles have been associated with diVeren-
tial Ab responses to other vaccines, including measles–
mumps–rubella (MMR) vaccine (Ovsyannikova et al. 2004,
2006). In US schoolchildren (mostly European Americans)
who received MMR vaccination, DRB1*08 was considered
unfavorable—being negatively associated with desirable
immune response (Ovsyannikova et al. 2004), which con-
trasted with its positive association with Ab response to
HBV vaccination here. Another study reported a disadvan-
tage for DRB1*0801 in primary biliary cirrhosis patients of
European descent (Donaldson et al. 2006). While predomi-
nance of Hispanics and HIV+ subjects in our study popula-
tion might be one of the reasons for seemingly inconsistent
Wndings between studies, MMR vaccine is quite diVerent
from HBV vaccine in that it uses attenuated viruses instead
Fig. 1 Distribution of nominal P values in the analyses of 88 single
nucleotide polymorphisms (SNPs) within three regions of the human
major histocompatibility complex (MHC) (Table S2). MHC class I
SNPs (n = 62) are mapped to HLA class I and neighboring genes,
including HCP5, HLA-C, and ZNRD1 previously associated with HIV-
1-related outcomes (see text). MHC class III (central MHC) SNPs
(n = 14) are mapped to TNF, LTA, and LTB, which encode TNF-,
lymphotoxic alpha, and lymphotoxic beta, respectively. MHC class II
SNPs (n = 12) are in non-coding sequences around HLA-DRB1,
-DQA1, and -DQB1. The nominal P values are based on Chi-square
tests of non-responders (serum antibody concentrations <10 mIU/mL
at week 28), responders (10–1,000 mIU/mL), and high responders
(>1,000 mIU/mL). All SNPs are sorted by their relative order (from
telomere to centromere) instead of actual distance on the short arm of
chromosome 6. For clarity, three spaces are introduced between MHC
blocks. Only a single SNP (rs2523685) in the 5 Xanking region of
HCP5 has trend for association (P =0 . 0 2 1 )Hum Genet (2009) 126:685–696 693
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of recombinant antigens. Moreover, DRB1*08 in our study
population was represented by at least three common alle-
les (DRB1*0801, *0802, and *0804) and only DRB1*0804
had the clearest impact on Ab response to HBV vaccine
(Table S2). In the absence of highly comparable data from
other studies, the relevance of DRB1*08 to HBV vaccina-
tion deserves further evaluation in larger populations.
In contrast to HLA alleles with well-deWned function,
the MHC SNPs are mostly within non-coding sequences
and are suitable for testing secondary hypotheses about rel-
evance of gene expression and tagging of other HLA alleles
(de Bakker et al. 2006; Listgarten et al. 2008; Miretti et al.
2005) not speciWcally captured in routine HLA genotyping.
Our selection of SNPs in MHC class I region was dictated
by recent studies, which have demonstrated the potential
inXuence of MHC SNPs on HIV-1 pathogenesis and dis-
ease progression (Catano et al. 2008; Dalmasso et al. 2008;
Fellay et al. 2007; Limou et al. 2009; Shrestha et al. 2009;
van Manen et al. 2009). Although multiple SNPs can tag a
few HLA class I alleles (e.g., B*5701) and serology groups
(e.g., A10), these SNPs had little overlap with the panel of
SNPs that can be used to reliably infer HLA class I alleles
(Listgarten et al. 2008). The critical role of protective HLA
class I alleles (e.g., B*5701 and B*5703) in immune con-
trol of HIV-1 infection (O’Brien and Nelson 2004; Tang
and Kaslow 2003) was expected to indirectly beneWt Ab
response to HBV vaccination if patients are not receiving
antiretroviral therapy. In analyses of MHC class I SNPs
(Fig. 1), the absence of any apparent association was some-
what consistent with the earlier observation that HLA class
I alleles and haplotypes were not associated with Ab
responses in the REACH cohort (also consisted mostly of
HIV-1-infected youth) (Wang et al. 2004). The new study
population assembled here was not suitable for testing the
indirect eVects produced by HLA class I genotypes,
because few HIV+ youth (less than 10%) had severe immu-
nodeWciency at the time of vaccination. The weak signal
produced by a single, non-coding SNP within the HCP5
gene is probably worth pursuing in larger, homogeneous
cohorts, as analyses of SNPs without well-established func-
tional attributes typically require stratiWcation by race.
In summary, both primary and secondary analyses of
HLA and related genotypes have reiterated multifactorial
inXuences on Ab responses to HBV vaccination in youth.
Recognition of immunodeWciency (the loss of CD4+ T
cells) and several HLA-DRB1 alleles as independent predic-
tors of Ab response highlights the importance of T-helper
cell-dependent pathways and HLA class II antigen presen-
tation to eVective vaccination using recombinant antigens.
This work has also paved the way for further high-through-
put SNP typing that may reveal additional factors, includ-
ing regulatory (non-coding) sequence variations commonly
found in immune response genes beyond the HLA region,
as well as coding sequence variations that are also common
in genes encoding killer immunoglobulin receptors (Bashirova
et al.  2006; Parham 2005). Systematic evaluation of
non-HLA genes can be informative, as studies of European
twins have already indicated that almost 59% of heritability
in Ab responses to HBsAg can be attributed to genetic vari-
ations beyond the HLA-DRB1 locus (Hohler et al. 2002a).
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